 | 09/09/2010 04:45:30 PM
ProMetic to Present at Rodman&Renshaw's Twelfth Annual Healthcare Conference
09/09/10 -- ProMetic Life Sciences Inc. today announced that Mr. Pierre Laurin, President and Chief Executive Officer, will present at Rodman&Renshaw's Twelfth Annual Healthcare Conference.
[Market Wire] |
| 09/09/2010 04:45:05 PM
Tengion Adds The Johns Hopkins Hospital as an Additional Clinical Trial Site For Its Phase I Neo-Urinary Conduit™ Clinical Trial
EAST NORRITON, Pa., Sept. 9 Tengion, Inc., a leader in regenerative medicine, announced today it has added The Johns Hopkins Hospital in Baltimore, Maryland as a second clinical trial site for its Phase I clinical trial of the Company's lead product candidate, the Tengion Neo-Urinary Conduit, in bladder cancer patients requiring bladder removal.
[PR Newswire] |
| 09/09/2010 04:45:01 PM
ProMetic to Present at Rodman&Renshaw's Twelfth Annual Healthcare Conference
MONTREAL, QUEBEC-- - ProMetic Life Sciences Inc. today announced that Mr. Pierre Laurin, President and Chief Executive Officer, will present at Rodman&Renshaw's Twelfth Annual Healthcare Conference.
[Marketwire (Canada)] |
| 09/09/2010 04:45:00 PM
NuPathe to Present at the Stifel Nicolaus 2010 Healthcare Conference
09/09/10 -- NuPathe Inc., a specialty pharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, including neurological and psychiatric disorders, today announces that Jane Hollingsworth, chief executive officer, will present a company overview at the Stifel Nicolaus 2010 Healthcare Conference on Thursday, Septembe...
[Market Wire] |
| 09/09/2010 04:44:17 PM
FDA Takes Appropriate Action to Regulate Electronic Cigarettes and Protect Public Health
WASHINGTON, Sept. 9 The following is a statement of Matthew L. Myers, President, Campaign for Tobacco-Free Kids: We applaud the U.S. Food and Drug Administration for taking appropriate enforcement action today against five distributors of electronic cigarettes for various violations of the Federal Food, Drug and Cosmetic Act, including unsubstantiated claims and poor manufacturing practices.
[PR Newswire] |
| 09/09/2010 04:43:01 PM
Achaogen to Present New Data on ACHN-490 at the 50th Annual ICAAC Meeting
Presentations Highlight Data from Phase 1 Study with ACHN-490 and In Vitro Activity of ACHN-490 Against Resistant Bacterial Pathogens and in Combination with Existing Antibiotics.
[Business Wire] |
| 09/09/2010 04:35:54 PM
China Pharma to Present at the Rodman&Renshaw Annual Global Investment Conference in New York on September 12 - 15, 2010
HAIKOU CITY, China, Sept. 9 China Pharma Holdings, Inc., a leading fully-integrated specialty pharmaceutical company in China, today announced that the Company's Chief Financial Officer, Mr. Frank Waung, has been invited to present at the Rodman&Renshaw Annual Global Investment Conference.
[PR Newswire] |
| 09/09/2010 04:30:08 PM
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS.
Going Concern. Results of Operations. Contract manufacturing revenue $ 983,000 $ 2,070,000 $ Contract Manufacturing Revenue.
[Edgar Glimpses] |
| 09/09/2010 04:30:01 PM
Genetix Pharmaceuticals Renamed bluebird bio; Announces Appointment of Nick Leschly as Chief Executive Officer
bluebird bio, an emerging leader in the development of innovative gene therapies for severe genetic disorders, today announced that it has changed the company name from Genetix Pharmaceuticals, Inc., to bluebird bio, Inc., effective immediately. "I am excited to lead the exceptional team we have assembled at bluebird bio," said Mr. Leschly.
[Business Wire] |
| 09/09/2010 04:16:00 PM
CytoGenix, Inc. Announces Expansion of Its Advisory Board
CytoGenix, Inc. announced today that it has expanded its Advisory Board. Stephen Udem, PhD, MD: Dr. Udem is an internationally recognized virologist and vaccinologist who previously served as Vice President of Wyeth Vaccines Research and a member of the Wyeth Vaccine Business Unit's Senior Management. Peter Glazer, MD, PhD. Sergio Rosini, PhD.
[Business Wire] |
| 09/09/2010 04:05:17 PM
Transcept Pharmaceuticals to Present at UBS Global Life Sciences Conference
POINT RICHMOND, Calif., Sept. 9 Transcept Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced that Transcept management is scheduled to present a general business overview at the UBS Global Life Sciences Conference in New York on S...
[PR Newswire] |
| 09/09/2010 04:02:13 PM
Myrexis Reports Fiscal Year 2010 Results
Robust Oncology Pipeline Advancing. Conference Call Today at 4:30pm ET. Upcoming Events. FY10 Highlights. SALT LAKE CITY, Sept. 9, 2010 -- Myrexis, Inc., a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today announced financial results for its fourth quarter and fiscal year ended June 30, 2010.
[GlobeNewswire] |
| 09/09/2010 04:01:09 PM
Zalicus To Present At The Rodman And Renshaw Annual Global Healthcare Conference
Zalicus Inc. a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, today announced that Mark Corrigan, President and CEO is scheduled to present at the Rodman and Renshaw Annual Global Healthcare Conference at 4:30pm EDT on September 14, 2010, at the New York Palace Hotel. About Zalicus.
[Business Wire] |
| 09/09/2010 04:00:00 PM
Peregrine Pharmaceuticals Reports First Quarter Fiscal Year 2011 Clinical Progress and Financial Results
09/09/10 -- Peregrine Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced its clinical progress and financial results for the first quarter ended July 31, 2010 for its fiscal year 2011 and provided an update on the progress with its development programs.
[Market Wire] |
| 09/09/2010 03:56:50 PM
FDA Approves Pediatric Use of Chemical Poisoning Treatment
SILVER SPRING, Md., Sept. 9 The U.S. Food and Drug Administration has approved the pediatric use of Protopam Chloride, a drug used to treat poisoning by organophosphate pesticides and chemicals.
[PR Newswire] |
| |
previous
|
next |
|
